Sava Infond d.o.o. Trims Stake in TransMedics Group, Inc. $TMDX

Sava Infond d.o.o. decreased its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 9.1% during the second quarter, according to its most recent filing with the SEC. The firm owned 2,000 shares of the company’s stock after selling 200 shares during the period. Sava Infond d.o.o.’s holdings in TransMedics Group were worth $268,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in TMDX. Two Sigma Investments LP purchased a new position in shares of TransMedics Group during the 4th quarter worth approximately $781,000. GAMMA Investing LLC grew its holdings in shares of TransMedics Group by 43,744.2% during the 1st quarter. GAMMA Investing LLC now owns 105,226 shares of the company’s stock worth $7,080,000 after acquiring an additional 104,986 shares during the period. NBC Securities Inc. purchased a new stake in shares of TransMedics Group in the 1st quarter worth approximately $25,000. SG Americas Securities LLC grew its stake in shares of TransMedics Group by 132.2% in the 1st quarter. SG Americas Securities LLC now owns 14,126 shares of the company’s stock worth $950,000 after buying an additional 8,043 shares during the last quarter. Finally, Campbell Newman Asset Management Inc. grew its stake in shares of TransMedics Group by 1.4% in the 1st quarter. Campbell Newman Asset Management Inc. now owns 11,619 shares of the company’s stock worth $782,000 after buying an additional 166 shares during the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Oppenheimer upped their price target on TransMedics Group from $130.00 to $150.00 and gave the stock an “outperform” rating in a research note on Tuesday, June 17th. Wall Street Zen downgraded TransMedics Group from a “buy” rating to a “hold” rating in a research note on Saturday, August 30th. Weiss Ratings restated a “hold (c)” rating on shares of TransMedics Group in a research note on Saturday, September 27th. Canaccord Genuity Group upped their price target on TransMedics Group from $129.00 to $142.00 and gave the stock a “buy” rating in a research note on Tuesday, July 15th. Finally, Morgan Stanley upped their price target on TransMedics Group from $115.00 to $123.00 and gave the stock an “equal weight” rating in a research note on Friday, August 1st. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, TransMedics Group currently has a consensus rating of “Moderate Buy” and an average target price of $125.40.

TransMedics Group Stock Performance

Shares of TMDX opened at $115.69 on Friday. The business’s fifty day simple moving average is $117.01 and its two-hundred day simple moving average is $110.32. The company has a current ratio of 9.86, a quick ratio of 9.17 and a debt-to-equity ratio of 1.61. TransMedics Group, Inc. has a 12 month low of $55.00 and a 12 month high of $146.98. The company has a market cap of $3.94 billion, a price-to-earnings ratio of 59.94 and a beta of 2.08.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Wednesday, July 30th. The company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.48 by $0.44. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%.The business had revenue of $157.37 million for the quarter, compared to the consensus estimate of $146.64 million. During the same period last year, the business posted $0.35 EPS. The company’s revenue was up 37.7% compared to the same quarter last year. TransMedics Group has set its FY 2025 guidance at EPS. Research analysts anticipate that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.